Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
560 daily bars · split adjusted
Current price $0.1026
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 26.44 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 36.96 | Oscillator | Neutral |
| Williams %R (14) | -70.39 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.07 (Hist 0.01) | Oscillator | Buy |
| Average Directional Index (14) | 47.27 (+DI 11.9 / -DI 36.6) | Trend | Strong Sell |
| EMA 20 | 0.16 | MA | Strong Sell |
| SMA 20 | 0.13 | MA | Strong Sell |
| EMA 50 | 0.31 | MA | Strong Sell |
| SMA 50 | 0.36 | MA | Strong Sell |
| SMA 200 | 0.77 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | ADGM | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.1x | -18.3x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.1x | EPS est. -1.09 | Elevated |
| Price / Book | -5.5x | -0.6x | Elevated |
| Price / Sales | — | 405.0x | Discount |
| EV / EBITDA | -0.9x | -4.3x | Discount |
| Return on equity | -661.9% | — | Weak |
| Gross margin | 0.0% | -329.5% | Below hist. |
| Debt / Equity | -62.65 | 0.44 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -6.70 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 27, 24 | Mirsaeedi-Farahani Keyvan | director | J-Other | 12,770 | — |
| Jun 16, 26 |
| Salmon Sean |
| director |
| A-Award |
| 30,000 @ $0.7103 |
| $21.31K |
| Jun 16, 26 | Mirsaeedi-Farahani Keyvan | director | A-Award | 30,000 @ $0.7103 | $21.31K |
| Jun 16, 26 | Cox James L | director | A-Award | 30,000 @ $0.7103 | $21.31K |
| Jun 16, 26 | Gardiner Sandra A. | director | A-Award | 30,000 @ $0.7103 | $21.31K |
| Jun 16, 26 | Mishan Orly | director | A-Award | 100,000 @ $0.7103 | $71.03K |
| Jun 16, 26 | Moran Timothy P. | director | A-Award | 30,000 @ $0.7103 | $21.31K |
| Mar 6, 26 | Kaster Deborah | officer: Chief Financial Officer | A-Award | 490,500 @ $0.977 | $479.2K |
Stock news · updated daily
Adagio Medical Holdings, Inc. (NASDAQ: ADGM - Get Free Report) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 412,796 shares, an increase of 59.3% from the August 31st total of 259,188 shares. Approximately 2.0% of the company's shares are short sold. Based on
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Board of Directors has completed a comprehensive review of the Company's business, programs, resources and capabilities and has initiated a formal process to explore strategic alternatives focused on maximizing shareholder value. In connection with this decision, t.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (âAdagioâ or âthe Companyâ), a leading innovator in catheter ablation technologies for the treatment of car
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced highlights from the first patient enrolled in the Company's study evaluating its next-generation vCLAS™ Ultra Ultra-Low Temperature Ablation (“ULTA”) Ventricular Ablation System. The study is designed to support a Premarket Approval (“PMA”) supplement to the Company's PMA f.
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. Recent Business Highlights: Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company's next-generation vCLAS™ Ultra Ultra-Low temperature ablation cat.
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (“ULTA”) system under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”).The patient, who presented with non-ischemic cardiomyopath.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -0.27 | -0.30 | Miss -11.1% | — |
| May 12, 2026 | -0.36 | -0.31 | Beat 13.9% | — |
| Mar 27, 2026 | -0.31 | -0.21 | Beat 32.3% | — |
| Nov 12, 2025 | -0.43 | -0.66 | Miss -53.5% | — |
| Aug 13, 2025 | — | -0.35 | — | — |
| May 15, 2025 | — | -0.50 | — | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 13, 2026 | 2026-10-13 06:19:25 | View |
| DEF 14A | Oct 13, 2026 | 2026-10-13 06:02:46 | View |
| 8-K | Oct 1, 2026 | 2026-10-01 17:08:10 | View |
| PRE 14A | Oct 1, 2026 | 2026-10-01 16:54:39 | View |
| 8-K | Sep 23, 2026 | 2026-09-23 08:01:31 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 17:04:24 | View |
| 8-K | Aug 14, 2026 | 2026-08-14 16:31:41 | View |
| 8-K | Aug 13, 2026 | 2026-08-13 16:37:14 | View |
| 4 | Aug 12, 2026 | 2026-08-12 14:37:39 | View |
| 4 | Aug 12, 2026 | 2026-08-12 13:58:55 | View |
Proxy statement (DEF 14A) disclosures